# Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia

Study · id `cardio:ct-nct02833844` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02833844](<https://clinicaltrials.gov/study/NCT02833844>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02833844

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 467 participants.

## Technical summary

Registry record NCT02833844. Randomized; quadruple masking; primary purpose treatment. Start 2017-05-22 (actual); primary completion 2019-07-09 (actual). Results posted on 2020-07-21.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 467 participants (enrolled count; ClinicalTrials.gov record NCT02833844, source copy `cardio:ctgov-nct02833844-2022-07-22`, retrieved 2026-10-31)
- Started: 2017-05-22 (actual) (ClinicalTrials.gov record NCT02833844, source copy `cardio:ctgov-nct02833844-2022-07-22`, retrieved 2026-10-31)
- Primary completion: 2019-07-09 (actual) (ClinicalTrials.gov record NCT02833844, source copy `cardio:ctgov-nct02833844-2022-07-22`, retrieved 2026-10-31)
- Completion: 2020-01-27 (actual) (ClinicalTrials.gov record NCT02833844, source copy `cardio:ctgov-nct02833844-2022-07-22`, retrieved 2026-10-31)
- Results first posted: 2020-07-21 (ClinicalTrials.gov record NCT02833844, source copy `cardio:ctgov-nct02833844-2022-07-22`, retrieved 2026-10-31)
- Countries: United States; Australia; Belgium; Brazil; Canada; France; Greece; Italy; Poland; Portugal; Romania; South Africa; Spain; Switzerland; United Kingdom (ClinicalTrials.gov record NCT02833844, source copy `cardio:ctgov-nct02833844-2022-07-22`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02833844-2022-07-22`, retrieved 2026-10-31)

## The registry's words

- Brief title: Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia
- Condition: Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection
- Intervention (Drug): Evolocumab
- Intervention (Drug): Placebo
- Lead sponsor: Amgen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry intervention name matches this record: Evolocumab (`cardio:evolocumab`)
- Registry lists this organization as the lead sponsor: Amgen (`cardio:org-amgen`)

## Provenance

Content hash: fac4f080ec256f031d24b6db89adaca7418022c12bf0117c66acee5937277089
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
